Lilly Drug Doubles Good Cholesterol in Race With Merck - BusinessWeek
Eli Lilly & Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
Good cholesterol, or HDL, sweeps the bad form of the fatty substance, known as LDL, out of arteries, reducing clogs. The treatment being developed by Indianapolis-based Lilly, evacetrapib, boosted HDL by as much as 129 percent and lowered bad cholesterol as much as 36 percent, the research found.
I know. If you’re too young Google will send you to car parts learn about Chocks. So, here’s a handy video.